Effectiveness of Early Favipiravir Therapy in Hospitalised COVID-19 Patients
COVID-19 is a disease caused by a novel coronavirus with no specific, standard treatment. We investigated the clinical data of COVID-19 patients admitted to King Fahad Specialist Hospital (KFSH) in Buraydah by comparing the patients who were treated early with favipiravir (within 3 days of admission...
Saved in:
Main Authors: | Abdulrahman Tawfik, Abdulrahman Alzahrani, Sami Alharbi, Jamal Almitairi, Arwa Alzahrani, Mohammed Ali Alshehri, Mohammed S. Aldughaim, Hani Alothaid |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | Advances in Virology |
Online Access: | http://dx.doi.org/10.1155/2022/9240941 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cardiac Injury Biomarkers and the Risk of Death in Patients with COVID-19: A Systematic Review and Meta-Analysis
by: Sami H. Alzahrani, et al.
Published: (2021-01-01) -
Advanced Computing Approach for Modeling and Prediction COVID-19 Pandemic
by: Sami A. Morsi, et al.
Published: (2022-01-01) -
The Impact of COVID-19 on Hospitalised COPD Exacerbations in Malta
by: Yvette Farrugia, et al.
Published: (2021-01-01) -
ST-segment elevation myocardial infarction hospitalisations remain unchanged during COVID-19
by: Chieh Yang Koo, et al.
Published: (2022-11-01) -
Antiviral and anti-inflammatory activities of favipiravir and quinine sulfate against dengue virus serotype 1 in vitro
by: Regita Aulia Rosalina, et al.
Published: (2025-03-01)